(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 4.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Anaptysbio's revenue in 2025 is $169,467,000.On average, 13 Wall Street analysts forecast ANAB's revenue for 2025 to be $5,950,805,972, with the lowest ANAB revenue forecast at $4,395,821,497, and the highest ANAB revenue forecast at $6,704,209,241. On average, 13 Wall Street analysts forecast ANAB's revenue for 2026 to be $3,775,046,000, with the lowest ANAB revenue forecast at $2,416,400,465, and the highest ANAB revenue forecast at $5,881,584,797.
In 2027, ANAB is forecast to generate $5,282,683,191 in revenue, with the lowest revenue forecast at $2,416,400,465 and the highest revenue forecast at $8,343,920,435.